English
Back
Open Account
2026 IPO bonanza! Over 90% of new stocks rose on their debut!
牛牛新股君
joined discussion ·

IPO Pricing | Mabwell-B debuts today with over 480 times subscription, priced at HKD 27.64 per share

Futu News April 28 update $MABWELL-B (02493.HK)$ Announced the allotment results, priced at HKD 27.64 per share, issuing a total of 47.1302 million shares, with each lot consisting of 200 shares, officially listed today.
In the last trading session, Maiwei Bio's grey market closed 3.11% higher at HKD 28.5 per share. With each lot containing 200 shares, excluding handling fees, investors made a profit of HKD 172 per lot.
During the public offering phase, Maiwei Bio received 481.71 times subscriptions. The final number of shares offered to the public amounted to 4.7132 million, representing approximately 10% of the total issued shares. A total of about 126,400 valid applications were received, with around 14,808 applications processed, and the approximate percentage of shares allocated in one lot compared to the total number of shares applied for was 1%.
Additionally, during the international placement phase, Maiwei Bio garnered 3.46 times subscriptions. The final number of shares in the international offering amounted to 42.417 million, equivalent to 90% of the total offering. Futu Information has compiled relevant data in the following table:
Futu News April 28 update $MABWELL-B (02493.HK)$ Announced the allotment results, priced at HKD 27.64 per share, issuing a total of 47.1302 million shares, with each lot consisting of 200 shares, officially listed today. In the last trading session, Maiwei Bio's grey market closed 3.11% higher at HKD 28.5 per share. With each lot containing 200 shares, excluding handling fees, investors made a profit of HKD 172 per lot. During the public offering phase, Maiwei Bio received 481.71 times subscriptions. The final number of shares offered to the public amounted to 4.7132 million, representing approximately 10% of the total issued shares. A total of about 126,400 valid applications were received, with around 14,808 applications processed, and the approximate percentage of shares allocated in one lot compared to the total number of shares applied for was 1%. Additionally, during the international placement phase, Maiwei Bio garnered 3.46 times subscriptions. The final number of shares in the international offering amounted to 42.417 million, equivalent to 90% of the total offering. Futu Information has compiled relevant data in the following table: Company Overview The company is a well-known Chinese pharmaceutical firm recognized for its innovative capabilities in drug research and development as well as its end-to-end operational expertise from drug discovery to commercial sales. The company’s pipeline focuses on cancer and age-related diseases, which pose significant global health risks and have unmet clinical needs. The company has built a competitive pipeline portfolio, including four marketed products across different categories and ten candidates awaiting approval...
Futu News April 28 update $MABWELL-B (02493.HK)$ Announced the allotment results, priced at HKD 27.64 per share, issuing a total of 47.1302 million shares, with each lot consisting of 200 shares, officially listed today. In the last trading session, Maiwei Bio's grey market closed 3.11% higher at HKD 28.5 per share. With each lot containing 200 shares, excluding handling fees, investors made a profit of HKD 172 per lot. During the public offering phase, Maiwei Bio received 481.71 times subscriptions. The final number of shares offered to the public amounted to 4.7132 million, representing approximately 10% of the total issued shares. A total of about 126,400 valid applications were received, with around 14,808 applications processed, and the approximate percentage of shares allocated in one lot compared to the total number of shares applied for was 1%. Additionally, during the international placement phase, Maiwei Bio garnered 3.46 times subscriptions. The final number of shares in the international offering amounted to 42.417 million, equivalent to 90% of the total offering. Futu Information has compiled relevant data in the following table: Company Overview The company is a well-known Chinese pharmaceutical firm recognized for its innovative capabilities in drug research and development as well as its end-to-end operational expertise from drug discovery to commercial sales. The company’s pipeline focuses on cancer and age-related diseases, which pose significant global health risks and have unmet clinical needs. The company has built a competitive pipeline portfolio, including four marketed products across different categories and ten candidates awaiting approval...
Company Overview
The company is a well-known Chinese pharmaceutical firm recognized for its innovative capabilities in drug research and development as well as its end-to-end operational expertise from drug discovery to commercial sales. The company’s pipeline focuses on cancer and age-related diseases, which pose significant global health risks and have unmet clinical needs.
The company has established a competitive portfolio of pipeline products, including four marketed products across different categories and ten drug candidates (one at the NDA stage, eight in clinical stages, and one in pre-clinical stage), focusing on oncology and age-related diseases such as immunology, ophthalmology, and orthopedics. Its core product, 9MW2821 (BFv, a Nectin-4 ADC), is one of the company’s ADC technology products, showcasing its expertise in this field.
Financial Summary
In 2024 and 2025, the company recorded revenues of RMB 199.6 million and RMB 659.0 million respectively; its R&D costs increased from RMB 782.9 million in 2024 to RMB 977.0 million in 2025; its gross profit rose from RMB 169.2 million in 2024 to RMB 596.4 million in 2025.
Futu News April 28 update $MABWELL-B (02493.HK)$ Announced the allotment results, priced at HKD 27.64 per share, issuing a total of 47.1302 million shares, with each lot consisting of 200 shares, officially listed today. In the last trading session, Maiwei Bio's grey market closed 3.11% higher at HKD 28.5 per share. With each lot containing 200 shares, excluding handling fees, investors made a profit of HKD 172 per lot. During the public offering phase, Maiwei Bio received 481.71 times subscriptions. The final number of shares offered to the public amounted to 4.7132 million, representing approximately 10% of the total issued shares. A total of about 126,400 valid applications were received, with around 14,808 applications processed, and the approximate percentage of shares allocated in one lot compared to the total number of shares applied for was 1%. Additionally, during the international placement phase, Maiwei Bio garnered 3.46 times subscriptions. The final number of shares in the international offering amounted to 42.417 million, equivalent to 90% of the total offering. Futu Information has compiled relevant data in the following table: Company Overview The company is a well-known Chinese pharmaceutical firm recognized for its innovative capabilities in drug research and development as well as its end-to-end operational expertise from drug discovery to commercial sales. The company’s pipeline focuses on cancer and age-related diseases, which pose significant global health risks and have unmet clinical needs. The company has built a competitive pipeline portfolio, including four marketed products across different categories and ten candidates awaiting approval...
Use of Proceeds
In terms of fund-raising purposes, Maiwei Bio expects to receive net proceeds from the global offering of approximately HKD 1.189 billion (based on the offer price of HKD 27.64). According to the prospectus, Maiwei Bio plans to allocate the proceeds from the global offering for the following purposes in the specified amounts:
Approximately 56.8% will be used for clinical development trials at various stages for its core product, 9MW2821, across multiple indications; around 17.7% will be allocated to the research and development of other pipeline products targeting cancers and age-related diseases with significant clinical needs; about 15.5% will be utilized for commercialization purposes; and roughly 10.0% will be applied toward working capital and other general corporate purposes.
The golden season for new stock subscriptions has arrived! Use Futu for new stock subscriptions—zero interest, zero handling fees, and zero cash subscription. Participants now have the chance to have their new stock subscription fees waived for a year.Come and experience it now >>
Futu News April 28 update $MABWELL-B (02493.HK)$ Announced the allotment results, priced at HKD 27.64 per share, issuing a total of 47.1302 million shares, with each lot consisting of 200 shares, officially listed today. In the last trading session, Maiwei Bio's grey market closed 3.11% higher at HKD 28.5 per share. With each lot containing 200 shares, excluding handling fees, investors made a profit of HKD 172 per lot. During the public offering phase, Maiwei Bio received 481.71 times subscriptions. The final number of shares offered to the public amounted to 4.7132 million, representing approximately 10% of the total issued shares. A total of about 126,400 valid applications were received, with around 14,808 applications processed, and the approximate percentage of shares allocated in one lot compared to the total number of shares applied for was 1%. Additionally, during the international placement phase, Maiwei Bio garnered 3.46 times subscriptions. The final number of shares in the international offering amounted to 42.417 million, equivalent to 90% of the total offering. Futu Information has compiled relevant data in the following table: Company Overview The company is a well-known Chinese pharmaceutical firm recognized for its innovative capabilities in drug research and development as well as its end-to-end operational expertise from drug discovery to commercial sales. The company’s pipeline focuses on cancer and age-related diseases, which pose significant global health risks and have unmet clinical needs. The company has built a competitive pipeline portfolio, including four marketed products across different categories and ten candidates awaiting approval...
Editor/Joe
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
129K Views
Report
Comments
Write a Comment...
10